Filing Analysis
MIRA Pharmaceuticals announced positive toxicokinetic findings from a 7-day repeated-dose study of its obesity drug candidate, SKNY-1, in Beagle dogs. The results demonstrate rapid oral absorption and dose-dependent systemic exposure, which the company believes de-risks dose selection for upcoming GLP toxicology studies.
๐ฉ Red Flags
- Preclinical data only; additional efficacy and safety studies are still required to characterize the drug candidate.
๐ Key Facts
- Study conducted on 7-day repeated-dose of SKNY-1 in male and female Beagle dogs.
- SKNY-1 demonstrated rapid oral absorption and dose-dependent systemic exposure.
- Plasma concentrations were comparable between male and female animals.
- Findings support advancement toward GLP-compliant toxicology studies required for IND-enabling development.
Mira Pharmaceuticals, Inc. received a notice from Nasdaq stating it is in violation of the minimum $1.00 bid price requirement. The company has been granted a 180-day compliance period ending January 25, 2027, to regain compliance.
๐ฉ Red Flags
- Failure to meet minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)).
- Potential for a mandatory reverse stock split to regain compliance.
- Risk of delisting if the company fails to cure the deficiency within the allotted timeframe.
๐ Key Facts
- Nasdaq issued a deficiency notice on July 27, 2026, due to the stock price falling below $1.00 for 30 consecutive business days ended July 24, 2026.
- The company has until January 25, 2027, to regain compliance by maintaining a minimum bid price of $1.00 for at least ten consecutive business days.
- A second 180-day compliance period may be available if the company can meet other listing standards and intends to cure the deficiency via a reverse stock split.
- The common stock continues to trade on the Nasdaq Capital Market under the symbol 'MIRA' during this period.
MIRA Pharmaceuticals, Inc. issued a press release under Item 7.01 announcing positive preclinical results for its oral drug candidate, MIRA-55. The study demonstrated favorable bioavailability and systemic exposure in optimized oral formulations.
๐ Key Facts
- Announced positive preclinical results for optimized oral formulations of MIRA-55 on July 10, 2026.
- MIRA-55 is being developed as a non-opioid therapy for chronic inflammatory pain.
- Lead formulation demonstrated favorable oral bioavailability and sustained systemic exposure.
- Pharmacokinetic profile showed reproducible distribution into both brain and liver tissue.
- Preclinical studies previously indicated MIRA-55 outperformed injected morphine in pain/inflammation models without THC-like CNS effects.
MIRA Pharmaceuticals, Inc. announced positive preclinical pharmacokinetic results for its oral drug candidate SKNY-1, targeting obesity and addiction. The studies showed favorable bioavailability and brain penetration, supporting a potential once-daily dosing regimen.
๐ Key Facts
- Preclinical studies evaluated the optimized oral formulation of SKNY-1.
- Results demonstrated favorable oral bioavailability and reproducible systemic exposure.
- Findings confirmed robust brain penetration and substantial liver exposure.
- Pharmacokinetics support a potential once-daily oral dosing schedule.
- The drug candidate targets obesity and addiction-related disorders.
MIRA Pharmaceuticals, Inc. issued a press release under Item 7.01 disclosing preclinical data for its cannabinoid analog, Mira-55. The data suggests the compound may offer anxiolytic activity and pain relief without the psychoactive side effects associated with THC.
๐ฉ Red Flags
- None identified in this filing.
๐ Key Facts
- Disclosed preclinical data for Mira-55, a cannabinoid analog targeting chronic inflammatory pain.
- Mira-55 did not produce locomotor suppression or catalepsy in standard preclinical models (unlike THC).
- Data showed anxiolytic activity rather than the anxiogenic activity observed with rimonabant.
- The mechanism of action appears distinct from classical CB1 agonism as body temperature reduction was not reversed by rimonabant.
MIRA Pharmaceuticals announced the submission of a Phase 2a clinical trial protocol (Protocol Mira-002) to the FDA for its proprietary oral NMDA receptor modulator, Ketamir-2, targeting chemotherapy-induced peripheral neuropathy (CIPN). The company also confirmed receipt of an acknowledgment from the FDA accepting the submission.
๐ Key Facts
- Submission date: June 17, 2026
- Drug candidate: Ketamir-2 (oral NMDA receptor modulator)
- Indication: Chemotherapy-induced peripheral neuropathy (CIPN)
- Trial Stage: Phase 2a
- Protocol Identifier: Protocol Mira-002
- FDA status: Acknowledgment of receipt confirmed
Mira Pharmaceuticals announced the departure of CFO Alan Weichselbaum and the appointment of Andriy Mushak as Fractional CFO effective June 6, 2026. Mr. Mushak is a partner at LMAM Consulting Group, LLC, and will provide services via a consulting agreement.
๐ฉ Red Flags
- Transition from a full-time CFO to a 'Fractional' CFO often indicates budget constraints or a reduction in the scale of financial operations in micro-cap companies.
๐ Key Facts
- Alan Weichselbaum ceased serving as CFO effective June 6, 2026.
- Andriy Mushak appointed as Fractional CFO effective June 6, 2026.
- Mr. Mushak is a CPA and Partner at LMAM Consulting Group, LLC.
- The Company will pay Mr. Mushak $6,000 per month for his services under a Consulting Agreement with LMAM.
- The departure of Mr. Weichselbaum was reportedly not due to any disagreement with the Company.
MIRA Pharmaceuticals entered into an Amended and Restated Exclusive License Agreement with MIRALOGX LLC on June 3, 2026. The agreement secures worldwide exclusive rights to intellectual property for the MIRA-55 and SKNY-1 development programs.
๐ Key Facts
- Agreement date: June 3, 2026
- Counterparty: MIRALOGX LLC
- Scope: Worldwide exclusive rights to develop, manufacture, use, sell, and commercialize products related to MIRA-55 and SKNY-1
- The company explicitly stated that the amended agreement does not materially modify previously disclosed core economic terms
MIRA Pharmaceuticals entered into Amendment No. 1 to its Exclusive License Agreement with MIRALOGX LLC on May 21, 2026, expanding the licensed territory for Ketamir-2 from North America to all countries where patent rights exist, including Europe, China, Japan, and others.
๐ Key Facts
- Amendment date: May 21, 2026
- Territory expansion: From US, Canada, and Mexico to all countries with patent rights
- Patent portfolio expansion: Now includes international filings in Europe, China, Japan, Canada, Australia, India, Israel, Mexico, and South Korea
- Strategic goal: Support global development and commercialization of Ketamir-2 heading toward Phase 2a development
- Financial terms: No material modification to core economic terms, royalty obligations, or financial consideration
MIRA Pharmaceuticals announced positive Phase 1 clinical trial results for Ketamir-2, its oral NMDA receptor modulator, demonstrating safety and tolerability in 57 healthy volunteers. The company is now preparing for Phase 2a trials and has received confirmation from the DEA that the drug is not a controlled substance.
๐ Key Facts
- Phase 1 study included 57 healthy volunteers across single ascending dose (SAD) and multiple ascending dose (MAD) cohorts.
- No serious adverse events or dose-limiting toxicities were reported; adverse events were predominantly mild.
- Pharmacokinetic data showed a half-life of 2.5 to 7 hours for Ketamir-2 and 7 to 9 hours for its active metabolite, supporting potential once-daily dosing.
- The U.S. DEA determined Ketamir-2 is not classified as a controlled substance.
- The company is advancing to Phase 2a clinical protocol submission for chemotherapy-induced peripheral neuropathy (CIPN).
MIRA Pharmaceuticals announced the publication of a peer-reviewed manuscript in the International Journal of Molecular Sciences detailing preclinical results for its drug candidate SKNY-1. The study demonstrated that SKNY-1, a THCV analog, produced significant weight loss and reduced nicotine-seeking behaviors in a zebrafish model.
๐ฉ Red Flags
- The data is strictly preclinical (zebrafish), which has a high rate of failure when transitioning to human clinical trials.
๐ Key Facts
- The manuscript is titled 'SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of Obesity.'
- SKNY-1 showed a 30% reduction in body weight relative to baseline in the higher-dose group over a six-day treatment period.
- The drug candidate demonstrated selective in vitro inhibition of monoamine oxidase B (MAO-B) and engagement of CB1 and CB2 receptors.
- Preclinical findings included normalization of cholesterol (LDL/HDL), reduction of hepatic triglycerides, and attenuation of compulsive feeding and nicotine-seeking behaviors.
- The research is currently limited to preclinical zebrafish models and in vitro systems; human safety and efficacy have not been established.
MIRA Pharmaceuticals reported positive preclinical data for its drug candidate Mira-55, demonstrating a lack of cannabinoid-related CNS side effects and reduced anxiety-like behavior. The company is leveraging these results to support an upcoming Investigational New Drug (IND) submission for inflammatory pain.
๐ Key Facts
- Preclinical study conducted in collaboration with Pharmaseed evaluated Mira-55 at doses of 10, 30, and 100 mg/kg.
- Mira-55 showed no evidence of sedation, catalepsy, or motor impairment, unlike THC or rimonabant.
- The drug candidate demonstrated a dose-dependent increase in time spent in open arms during Elevated Plus Maze (EPM) testing, suggesting reduced anxiety.
- Previous data indicated Mira-55 provides morphine-comparable analgesic effects without opioid-related risks.
- The company is currently advancing Mira-55 toward an IND submission for inflammatory pain.
MIRA Pharmaceuticals announced the completion of Phase 1 dosing for Ketamir-2, its proprietary oral NMDA receptor modulator. The study in 56 healthy volunteers showed no serious adverse events or dissociative effects, clearing the path for a Phase 2a submission in the first half of 2026.
๐ Key Facts
- Completed Phase 1 dosing for Ketamir-2 in 56 healthy adult volunteers at Hadassah Medical Center.
- The study included Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts with doses up to 600 mg.
- No serious adverse events (SAEs), dose-limiting toxicities (DLTs), or dissociative/psychotomimetic effects were reported.
- Company plans to submit Phase 2a clinical study documentation to the FDA in H1 2026.
- The upcoming Phase 2a study will target moderate to severe chemotherapy-induced peripheral neuropathy (CIPN).
Mira Pharmaceuticals announced the initiation of dosing in the final cohort of its Phase 1 clinical trial for Ketamir-2, its lead oral NMDA receptor antagonist. The company expects to complete the Phase 1 program by the end of Q1 2026 and plans to seek FDA Fast Track designation for this asset.
๐ Key Facts
- Initiated dosing in the final cohort (6 subjects remaining) of the Ketamir-2 Phase 1 MAD clinical trial.
- 50 healthy volunteers have already been dosed in the study to date.
- Phase 1 program completion expected by end of Q1 2026.
- Plans to submit Phase 2a protocol for CIPN (chemotherapy-induced peripheral neuropathy) following Phase 1 completion.
- Anticipated initiation of Phase 2a study in Q2 2026, subject to regulatory feedback.
- Intent to pursue FDA Fast Track designation for Ketamir-2.
- Plans to engage in partnering discussions at the BIO Summit in March 2026 and present data at AACR in April 2026.
- Preclinical programs SKNY-1 (weight loss/nicotine) and MIRA-55 (inflammatory pain) are undergoing CMC optimization with IND-enabling goals by year-end 2026.
MIRA Pharmaceuticals, Inc. announced the approval of various incentive awards for CEO Erez Aminov following significant company milestones in 2025.
๐ฉ Red Flags
- None identified in this specific filing.
๐ Key Facts
- Compensation Committee approved a $242,258 short-term incentive (STI) payout for CEO Erez Aminov on December 16, 2025.
- An additional $80,753 STI is contingent upon the completion of an ongoing Phase 1 clinical study.
- A transaction advisory award of $915,000 was approved in recognition of the SKNY Pharmaceutical, Inc. acquisition; payable in cash, equity, or both.
- 62,500 performance share units (PSUs) were issued to the CEO following achievement of a market capitalization milestone under his LTI plan.
MIRA Pharmaceuticals, Inc. has filed a prospectus supplement to increase its At The Market (ATM) offering capacity by an additional $15,241,591. This follows a previous sale of approximately $7.03 million in common stock under the same Sales Agreement.
๐ฉ Red Flags
- Potential dilution for existing shareholders due to increased ATM offering capacity
- Continuous need for capital raises (indicated by the increase in aggregate amount over previous sales)
๐ Key Facts
- Increased maximum aggregate offering amount: $15,241,591
- Previous shares sold under Sales Agreement: $7,034,658
- Counterparty: Rodman & Renshaw LLC
- Original Sales Agreement date: August 12, 2024 (amended September 24, 2024)
- Security type: Common Stock ($0.0001 par value)
MIRA Pharmaceuticals has initiated the Multiple Ascending Dose (MAD) portion of its Phase 1 clinical trial for Ketamir-2 and selected chemotherapy-induced peripheral neuropathy (CIPN) as its lead Phase 2a indication. The company reports that no serious adverse events were observed during the preceding Single Ascending Dose (SAD) phase.
๐ Key Facts
- Initiated Multiple Ascending Dose (MAD) portion of Phase 1 study for Ketamir-2 in healthy volunteers.
- Selected chemotherapy-induced peripheral neuropathy (CIPN) as lead Phase 2a indication.
- SAD (Single Ascending Dose) phase completed with no serious or dose-limiting adverse events reported.
- MAD phase includes three cohorts of repeat daily oral dosing (150 mg to 600 mg for five days).
- Ketamir-2 is a non-scheduled, oral analog of ketamine designed to avoid psychoactive/hallucinogenic effects.
MIRA Pharmaceuticals, Inc. completed a block sale of 1,751,000 common shares via its at-the-market (ATM) offering facility on October 16, 2025. The shares were sold to institutional investors at an average price of $2.19 per share.
๐ฉ Red Flags
- Use of ATM offering can indicate a need for immediate liquidity to fund operations, common in micro-cap biotech/pharma companies.
๐ Key Facts
- Total shares sold: 1,751,000 common stock shares.
- Average sale price: $2.19 per share (representing a 66% premium to the prior day's closing price).
- Gross proceeds: Approximately $3,835,485 (before fees and expenses).
- Method of sale: Block sales via at-the-market (ATM) equity offering facility.
- Facilitator: Rodman & Renshaw via the StockBlock platform.
MIRA Pharmaceuticals announced positive preclinical data for its proprietary non-psychotropic marijuana analog, Mira-55. The study indicates that oral administration of Mira-55 outperformed injected morphine in normalizing pain and reducing inflammation in animal models.
๐ Key Facts
- Preclinical data shows oral Mira-55 normalized pain and significantly reduced inflammation.
- Mira-55 outperformed injected morphine in an established animal model of chronic inflammatory pain.
- The study demonstrated a direct CB2-receptor-mediated anti-inflammatory mechanism via oral administration.
- Findings support the Company's plan to pursue an Investigational New Drug (IND) application for chronic inflammatory pain.
MIRA Pharmaceuticals completed the acquisition of SKNY Pharmaceuticals via a stock-for-stock merger, which included a $5 million contribution of marketable securities to MIRA. The filing also addresses recent Nasdaq compliance issues regarding stockholders' equity.
๐ฉ Red Flags
- History of non-compliance with Nasdaq minimum stockholders' equity requirements (Rule 5550(b)(1)).
- Risk of delisting remains if compliance is not evidenced in the next periodic report.
- Dilution risk due to issuance of restricted shares for the acquisition.
๐ Key Facts
- Completed acquisition of 100% of SKNY Pharmaceuticals on September 29, 2025.
- Consideration consisted of restricted shares of MIRA common stock issued to SKNY shareholders.
- SKNY contributed $5 million in marketable securities to MIRA as a condition to closing.
- Acquisition adds three pipeline candidates: Ketamir-2 (Phase 1), MIRA-55, and SKNY-1.
- Company reports it has regained compliance with Nasdaq Listing Rule 5550(b)(1) regarding the $2.5M minimum stockholders' equity requirement.
MIRA Pharmaceuticals announced positive topline results from the Phase 1 Single Ascending Dose (SAD) study of its oral Ketamir-2. The drug demonstrated a favorable safety profile and predictable pharmacokinetic properties in healthy volunteers.
๐ Key Facts
- Phase 1 SAD study enrolled 32 healthy adult participants across four dose cohorts (50 mg to 600 mg).
- Ketamir-2 showed dose-proportional increases in exposure (Cmax and AUC) with no dose-limiting toxicities.
- Pharmacokinetics: Tmax reached within 1โ2 hours; terminal half-life of Ketamir-2 was 2 to 5 hours.
- The drug's primary active metabolite, nor-Ketamir, has a half-life of 6.5 to 8.5 hours.
- The US DEA concluded that Ketamir-2 will not be considered a controlled substance under the Controlled Substances Act.
- Company is proceeding to Multiple Ascending Dose (MAD) portion and subsequent Phase 2a trials for neuropathic pain.
Mira Pharmaceuticals reported positive proof-of-concept preclinical data for its drug candidate Ketamir-2 in an animal model of PTSD. The study showed that oral dosing reversed anxiety and depressive-like behaviors in stressed rats.
๐ Key Facts
- Ketamir-2 was administered orally once daily for five consecutive days in a Single Prolonged Stress (SPS) rat model.
- Results showed a reversal of avoidance, anxiety-like, and depressive-like behaviors toward levels seen in non-stressed animals.
- The drug is currently in an ongoing Phase 1 clinical trial for neuropathic pain with a favorable safety profile reported to date.
- The U.S. DEA has concluded Ketamir-2 would not be considered a controlled substance or listed chemical.
MIRA Pharmaceuticals, Inc. held its 2025 Annual Meeting of Stockholders where shareholders approved the acquisition of SKNY Pharmaceuticals, Inc. and amendments to the company's 2022 Omnibus Incentive Plan.
๐ฉ Red Flags
- Approval of option/SAR repricing allows management to lower exercise prices, which can be dilutive and potentially non-aligned with minority shareholders.
- The acquisition involves a significant issuance of shares (over 20% of MIRA common stock) per Nasdaq Listing Rule 5635(a).
๐ Key Facts
- Shareholders approved the acquisition of SKNY Pharmaceuticals, Inc., a transaction expected to close shortly.
- SKNY will contribute $5 million in cash or assets to MIRA upon closing.
- Independent valuation by Moore Financial Consulting estimated SKNY enterprise value at ~$30.5M and MIRA at ~$30M.
- Shareholders approved increasing the 2022 Omnibus Incentive Plan share reserve from 5,000,000 to 8,000,000 shares.
- The plan amendment allows for the repricing of options or stock appreciation rights (SARs).
- Quorum was established with 10,588,211 shares voted, representing ~55.52% of outstanding votes.
MIRA Pharmaceuticals announced the successful completion of the Single Ascending Dose (SAD) portion of its Phase 1 clinical trial for oral Ketamir-2. The company reported no severe or clinically significant adverse effects and is proceeding to the Multiple Ascending Dose (MAD) stage.
๐ Key Facts
- Completed SAD portion of Phase 1 trial for oral Ketamir-2 in healthy volunteers.
- Trial enrolled 32 participants across four dose cohorts (50 mg to 600 mg).
- No severe or clinically significant adverse effects observed at any dose level based on blinded data.
- Proceeding to Multiple Ascending Dose (MAD) stage involving up to 24 participants receiving daily doses for five days.
- FDA IND clearance previously received for neuropathic pain indication.
- U.S. Phase 2a trial expected to initiate in Q4 2025, pending results and regulatory review.
MIRA Pharmaceuticals announced that a manuscript regarding its lead drug candidate, Ketamir-2, has been accepted for publication in the peer-reviewed journal Frontiers in Pharmacology. The study demonstrates superior efficacy of Ketamir-2 compared to ketamine, gabapentin, and pregabalin in preclinical neuropathic pain models.
๐ Key Facts
- Manuscript accepted by 'Frontiers in Pharmacology' regarding Ketamir-2 efficacy.
- Preclinical data shows Ketamir-2 outperformed ketamine, pregabalin, and gabapentin in restoring sensory function/reversing pain behaviors.
- Company plans to submit a Phase 2a clinical trial protocol to the FDA in Q4 2025.
- Goal is to initiate neuropathic pain studies by year-end 2025.
- The global neuropathic pain market is projected to reach $16.79 billion by 2034.
MIRA Pharmaceuticals announced positive preclinical data for its topical Ketamir-2 formulation, demonstrating analgesic efficacy comparable to injected morphine in rodent pain models. The study showed significant reduction in both acute and inflammatory pain behaviors.
๐ Key Facts
- Preclinical study used a formalin injection model in rodents to test Topical Ketamir-2 cream.
- Topical Ketamir-2 nearly eliminated paw licking (active response) and significantly reduced paw lifting (passive avoidance) in Phase 1 (0โ10 min).
- In Phase 2 (15โ60 min), the formulation showed comparable overall pain suppression to morphine-treated animals.
- The company is currently conducting a Phase 1 clinical trial of oral Ketamir-2 in healthy volunteers.
- A Phase 2a study in neuropathic pain is expected to begin later in 2025.
MIRA Pharmaceuticals announced FDA clearance of its Investigational New Drug (IND) application for Ketamir-2, a non-opioid drug candidate for neuropathic pain. This clearance allows the company to begin U.S.-based clinical trials following the completion of Phase 1 studies.
๐ Key Facts
- FDA cleared IND application for Ketamir-2 (oral NMDA receptor antagonist) for neuropathic pain treatment.
- Ketamir-2 demonstrated superior efficacy to gabapentin and pregabalin in preclinical models.
- Preclinical data showed no evidence of ketamine-associated neurotoxicity or dissociative side effects.
- Company is nearing completion of the single ascending dose (SAD) portion of international Phase 1 trials.
- U.S.-based Phase 2a efficacy trial is planned for launch in Q4 2025.
- Planned acquisition of SKNY Pharmaceuticals, Inc. remains on track.
MIRA Pharmaceuticals announced positive preclinical results for SKNY-1, an oral drug candidate for obesity and nicotine addiction, which is currently under a definitive agreement to be acquired by the company. The study demonstrated that SKNY-1 reverses anxiety-related behavior in zebrafish models without the CNS side effects seen in previous CB1-targeting drugs.
๐ฉ Red Flags
- The acquisition is pending shareholder approval, meaning the transaction is not yet finalized.
๐ Key Facts
- SKNY-1 showed reversal of anxiety-induced behavior in zebrafish light-dark preference tests.
- The drug candidate is under a definitive agreement for acquisition by MIRA Pharmaceuticals.
- SKNY-1 utilizes biased CB1 antagonism to avoid psychiatric side effects seen in historical drugs like Rimonabant.
- MIRA is preparing for shareholder approval regarding the proposed acquisition of SKNY Pharmaceuticals, Inc.
- Post-acquisition, the company expects to initiate IND-enabling studies for SKNY-1.
MIRA Pharmaceuticals, Inc. completed a block sale of 1,550,741 common shares to an institutional investor via its at-the-market (ATM) equity offering facility on July 3, 2025.
๐ฉ Red Flags
- Use of ATM offerings is often a sign of immediate liquidity needs to fund operations in micro-cap biotech companies.
๐ Key Facts
- Sold 1,550,741 shares of common stock in block sales.
- Average sale price was $1.2981 per share.
- Gross proceeds totaled approximately $2.0 million (before fees and expenses).
- The transaction occurred through an at-the-market (ATM) equity offering facility.
- Facilitated by Rodman & Renshaw via the StockBlock platform.
MIRA Pharmaceuticals announced positive preclinical results for its drug candidate Mira-55, demonstrating morphine-comparable pain relief in animal models without psychoactive effects. The company also reported progress on its acquisition of SKNY Pharmaceuticals and noted the SEC's completion of its review of the merger proxy.
๐ Key Facts
- Mira-55 (non-psychoactive marijuana analog) showed efficacy comparable to morphine in a formalin-based rodent model for inflammatory pain.
- Mira-55 targets CB2 receptors and avoids CB1 receptor activity, minimizing psychoactive side effects.
- The DEA has confirmed Mira-55 is not classified as a controlled substance.
- MIRA is progressing toward an Investigational New Drug (IND) submission for Mira-55.
- SKNY Pharmaceuticals acquisition: SKNY-1 showed 30% body weight reduction and reversal of nicotine cravings in studies.
- The SEC has completed its review of the merger proxy with no comments.
MIRA Pharmaceuticals announced positive preclinical animal study results for SKNY-1, a drug candidate it is currently in the process of acquiring from SKNY Pharmaceuticals, Inc. The studies showed significant weight loss and reduction in nicotine cravings in zebrafish models.
๐ฉ Red Flags
- Asset acquisition is still pending completion (under definitive agreement but not yet closed).
๐ Key Facts
- SKNY-1 demonstrated ~30% body weight reduction in 6 days in animal models.
- The drug candidate shows potential for both obesity treatment and smoking cessation (nicotine craving reversal).
- Preclinical data suggests preservation of lean muscle mass despite weight loss.
- The company is under a definitive agreement to acquire SKNY Pharmaceuticals, Inc., the developer of SKNY-1.
- Target market for combined obesity/smoking cessation applications exceeds $200 billion.
MIRA Pharmaceuticals, Inc. announced a definitive agreement to acquire SKNY Pharmaceuticals, Inc., which holds the drug candidate SKNY-1. The filing also provides updated preclinical in vitro data for SKNY-1, highlighting a 'biased antagonist' profile intended to treat weight loss and addiction without the psychiatric side effects of previous CB1 blockers.
๐ฉ Red Flags
- The acquisition is subject to regulatory review and shareholder approval, introducing execution risk.
- Data provided is limited to in vitro (test tube) studies; in vivo (animal) results are still pending.
๐ Key Facts
- MIRA has signed a definitive agreement to acquire SKNY Pharmaceuticals, Inc.
- The acquisition is subject to regulatory review and shareholder approval.
- Preclinical in vitro data for SKNY-1 shows selective inhibition of the ฮฒ-arrestin signaling pathway at the CB1 receptor.
- SKNY-1 demonstrated higher affinity partial agonist activity at the CB2 receptor, relevant for metabolic regulation.
- The compound showed low-affinity inhibition of MAO-B and did not inhibit MAO-A or dopamine receptors (D1, D2, D3).
- In vivo animal studies are currently being finalized to evaluate weight loss and nicotine addiction effects.
MIRA Pharmaceuticals announced that its lead drug candidate, Ketamir-2, has been accepted for publication in the peer-reviewed journal Frontiers in Pharmacology. The filing also provides updates on Phase 1 clinical trials and the progress of the SKNY Pharmaceuticals acquisition.
๐ Key Facts
- Ketamir-2 (lead drug candidate) to be published in 'Frontiers in Pharmacology' regarding its pharmacological profile.
- Phase 1 clinical trial for Ketamir-2 is progressing with dose escalation and no reported safety concerns.
- A Phase 2a trial for neuropathic pain is expected to initiate by year-end 2025, pending regulatory clearance.
- The acquisition of SKNY Pharmaceuticals (SKNY-1) is on track; SEC filings for the merger have been submitted.
MIRA Pharmaceuticals announced its participation in the BIO International Convention 2025 to pursue strategic partnerships and M&A. The company also provided clinical updates on Ketamir-2 and noted that it is finalizing regulatory filings for the acquisition of SKNY Pharmaceuticals, Inc.
๐ Key Facts
- Participating in BIO International Convention 2025 (June 16โ19) to explore licensing, collaborations, and M&A.
- Ketamir-2 Phase 1 clinical trial: second dosing cohort completed; third cohort preparation underway.
- Anticipated Phase IIa clinical trial for Ketamir-2 in neuropathic pain by end of 2025.
- Preclinical studies ongoing for Ketamir-2 in PTSD models and topical formulation efficacy.
- Finalizing regulatory filings for the acquisition of SKNY Pharmaceuticals, Inc. (SKNY).
- SKNY's lead candidate is SKNY-1, targeting smoking cessation and obesity.
MIRA Pharmaceuticals, Inc. announced the mutual separation of CFO Michelle Yanez and the appointment of Alan Weichselbaum as the new Chief Financial Officer. The transition is effective May 16, 2025, with the new CFO scheduled to start on May 19, 2025.
๐ฉ Red Flags
- Sudden departure of CFO (even if characterized as mutual separation).
- Relatively low base salary ($60,000) for a CFO in a public company may reflect tight liquidity/cash constraints typical of micro-cap biotech.
๐ Key Facts
- Michelle Yanez resigned as CFO, Treasurer, and Secretary effective May 16, 2025 (mutual separation).
- Alan Weichselbaum appointed as CFO effective May 15, 2025; start date May 19, 2025.
- New CFO Alan Weichselbaum is a CPA/MBA with over 30 years of experience in corporate finance and capital markets.
- Employment agreement for new CFO includes an annual salary of $60,000 and up to 75,000 stock options vesting over 12 months.
- The company stated the departure of Ms. Yanez was not based on any disagreement with the Company.
MIRA Pharmaceuticals, Inc. has entered into a definitive agreement to acquire SKNY Pharmaceuticals, Inc., a private biotech firm focused on obesity and nicotine dependence therapies. The transaction involves an enterprise value swap and a $5 million capital infusion from SKNY to MIRA.
๐ฉ Red Flags
- The transaction involves an enterprise value swap between two companies of similar size, which can lead to significant dilution for existing MIRA shareholders.
- The acquisition is subject to shareholder approval, introducing execution risk.
๐ Key Facts
- Acquisition of SKNY Pharmaceuticals, Inc. approved by Board on April 30, 2025.
- SKNY Enterprise Value: ~$30.5 million.
- MIRA Enterprise Value: ~$30 million.
- SKNY to contribute $5,000,000 in assets or cash to MIRA at closing with no contingencies.
- Transaction is subject to shareholder approval via a preliminary proxy statement (Form 14A).
- Valuations conducted by Moore Financial Consulting.
MIRA Pharmaceuticals announced successful results from a regulatory-required neurotoxicity study for its drug candidate, Ketamir-2. The study demonstrated that the compound did not induce brain lesions or mortality in animal models, addressing historical safety concerns associated with this class of drugs.
๐ Key Facts
- Completed a regulatory-required neurotoxicity study of Ketamir-2 (oral NMDA receptor antagonist).
- Study conducted on sexually mature Sprague-Dawley rats using high oral doses.
- No test article-related mortality or adverse clinical signs were observed in the Ketamir-2 group.
- No microscopic or macroscopic brain lesions were detected in treated groups, unlike the MK-801 positive control which showed Olney-type lesions.
- Results to be submitted to the FDA as part of ongoing regulatory communications.
MIRA Pharmaceuticals announced a successful in vitro release testing (IVRT) milestone for its topical formulation of Ketamir-2, demonstrating consistent drug release. This development expands the company's pipeline to include both oral and topical delivery methods for pain management.
๐ Key Facts
- Successful dose-proportional drug release demonstrated in a validated laboratory study for topical Ketamir-2.
- The formulation uses a hydrophobic base, successfully overcoming common water-soluble compound challenges.
- Company is initiating preclinical efficacy studies to assess therapeutic effects on inflammatory and neuropathic pain.
- MIRA is evaluating the program for potential FDA Fast Track designation.
- Oral Ketamir-2 is currently in Phase 1 trials; Phase 2a (diabetic neuropathy) expected later this year.
MIRA Pharmaceuticals announced positive preclinical study results for its oral ketamine analog, Ketamir-2, in a rat model of diabetic neuropathy. The data showed significant reduction in neuropathic pain symptoms and supports the company's plan to initiate Phase IIa trials by year-end 2025.
๐ Key Facts
- Preclinical study used a high-fat diet and Streptozotocin (STZ) rat model of type 2 diabetes.
- Ketamir-2 showed statistically significant reduction in neuropathic pain symptoms compared to untreated controls.
- A subset of treated animals returned to pre-diabetic baseline sensitivity levels.
- The company plans to initiate a Phase IIa trial in diabetic neuropathy patients by the end of 2025.
- Ketamir-2 is currently undergoing a Phase I clinical trial in healthy volunteers.
MIRA Pharmaceuticals received a notice from Nasdaq indicating it is non-compliant with the minimum stockholders' equity requirement of $2.5 million, having reported only $2,199,750 as of December 31, 2024. The company has until May 23, 2025, to submit a compliance plan and is relying on an upcoming acquisition and strategic investment to restore equity levels.
๐ฉ Red Flags
- Delisting notice/non-compliance with minimum stockholders' equity requirement.
- Capital deficiency: Current equity ($2.19M) is below the Nasdaq threshold ($2.5M).
- Reliance on a pending acquisition (SKNY Pharmaceuticals) to solve liquidity/equity issues.
๐ Key Facts
- Nasdaq deficiency notice received April 8, 2025, regarding Nasdaq Listing Rule 5550(b)(1).
- Stockholders' equity was $2,199,750 as of December 31, 2024 (below the $2.5 million requirement).
- The company has a deadline of May 23, 2025, to submit a compliance plan.
- Potential for an extension of up to 180 days upon Nasdaq review.
- Anticipated acquisition of SKNY Pharmaceuticals, Inc. is expected to include a $5 million capital infusion.
Mira Pharmaceuticals, Inc. announced the enrollment of the first subjects in its Phase 1 clinical trial for Ketamir-2, an oral ketamine analog targeting neuropathic pain. The study is a randomized, double-blind, placebo-controlled trial assessing safety and pharmacokinetics in healthy volunteers.
๐ Key Facts
- First subjects enrolled in Phase 1 clinical trial for Ketamir-2 (oral ketamine analog).
- Trial location: Clinical Pharmacology Unit of Hadassah Medical Center in Jerusalem, Israel.
- Study design: Randomized, double-blind, placebo-controlled study with 56 subjects.
- Cohorts include Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD).
- Phase 1 completion anticipated by Q4 2025.
- Phase 2a trial initiation targeted for year-end 2025.
- First human efficacy data expected in H1 2026.
MIRA Pharmaceuticals, Inc. entered into a binding Letter of Intent (LOI) to acquire SKNY Pharmaceuticals, Inc. via a stock exchange transaction. The deal includes a $5 million capital infusion from SKNY and aims to add the drug candidate SKNY-1 to MIRA's pipeline.
๐ฉ Red Flags
- Transaction contingency: The deal depends on an independent valuation, creating uncertainty regarding the exchange ratio and final structure.
- Dilution risk: A stock-for-stock merger will result in significant dilution for existing MIRA shareholders once the exchange ratio is determined.
๐ Key Facts
- Entered into a binding LOI with SKNY Pharmaceuticals on March 19, 2025.
- Transaction structure: Stock exchange where SKNY shareholders receive MIRA common stock.
- SKNY will provide a $5 million capital infusion in cash or cash equivalents to MIRA.
- The acquisition is contingent upon an independent third-party valuation determining SKNY's value is โฅ MIRA's value.
- Subject to shareholder approval from both companies and a 90-day due diligence period.
Mira Pharmaceuticals announced the successful formulation of Ketamir-2 into a topical treatment for localized neuropathic and inflammatory pain. This expands their pipeline beyond the existing oral formulation currently in Phase 1 trials.
๐ Key Facts
- Successful formulation of Ketamir-2 as a topical treatment for localized neuropathic and inflammatory pain.
- Topical version is designed for slow release to minimize systemic exposure.
- Preclinical studies are currently underway to assess efficacy for inflammatory pain.
- Company is preparing for a Phase 2a study in diabetic neuropathy by year-end (2025).
- Goal of obtaining first human efficacy data from the Phase 2a study by Q1 2026.
Mira Pharmaceuticals announced regulatory approval and the initiation of a Phase 1 clinical trial for Ketamir-2, an oral ketamine analog for neuropathic pain. The study will take place in Israel with recruitment starting in Q1 2025.
๐ฉ Red Flags
- Clinical development timeline in the U.S. remains contingent on pending neurotoxicity study results from the FDA (expected Q2 2025).
๐ Key Facts
- Received regulatory approval from the Israeli Ministry of Health and IRB to initiate Phase 1 trial for Ketamir-2.
- The randomized, double-blind, placebo-controlled study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers.
- Trial location: Hadassah Medical Center in Jerusalem, Israel.
- Subject recruitment is scheduled to begin in Q1 2025.
- Phase 1 is expected to conclude by Q4 2025.
- The company is awaiting FDA-required neurotoxicity study results, expected by Q2 2025, before initiating U.S. patient dosing.
MIRA Pharmaceuticals, Inc. announced the resignation of its independent auditor, Cherry Bekaert LLP, and the subsequent engagement of Salberg & Company P.A. The filing notes that previous audits included an explanatory paragraph regarding the company's ability to continue as a going concern.
๐ฉ Red Flags
- Auditor change (resignation) combined with previous going concern language.
- Presence of material weaknesses in internal control over financial reporting for the last two fiscal years.
- Previous audit opinions contained explanatory paragraphs regarding ability to continue as a going concern.
๐ Key Facts
- Cherry Bekaert LLP resigned as the independent registered public accounting firm on December 16, 2024.
- Salberg & Company P.A. was engaged as the new auditor on December 18, 2024, for the fiscal year ending December 31, 2024.
- Previous audits for years ended Dec 31, 2023, and 2022 included an explanatory paragraph regarding 'going concern' ability.
- Cherry Bekaert advised the company of material weaknesses in internal control over financial reporting as of December 30, 2023, and 2022.
- The company states there were no disagreements with Cherry Bekaert on accounting principles or auditing scope.
MIRA Pharmaceuticals, Inc. announced the submission of an Investigational New Drug (IND) application to the FDA for Ketamir-2, a novel oral ketamine analog intended for neuropathic pain. The company anticipates initiating Phase I clinical trials in Q1 2025.
๐ Key Facts
- Submitted IND application for Ketamir-2 (oral ketamine analog) on December 19, 2024.
- Target indication: Neuropathic pain.
- Phase I clinical trials expected to initiate in Q1 2025.
- Phase IIa trials anticipated for late 2025.
- Preclinical studies reported no adverse safety findings and potential for full pain reversal.
MIRA Pharmaceuticals announced the successful completion of its GLP preclinical safety program for Ketamir-2, a novel oral ketamine analog. The results showed no adverse findings across cardiovascular, CNS, and respiratory systems, clearing the way for an IND submission by year-end 2024.
๐ Key Facts
- Preclinical safety studies for Ketamir-2 demonstrated no adverse findings in dogs (cardiovascular) or rats (CNS/respiratory).
- 14-day toxicology in dogs showed the drug was well-tolerated at daily doses up to 200 mg/kg.
- Ames Test confirmed Ketamir-2 is non-mutagenic.
- Company plans to submit an Investigational New Drug (IND) application by the end of 2024.
- Phase I clinical trials are targeted for Q1 2025, with early data expected in Q2 2025.
MIRA Pharmaceuticals, Inc. announced the resignation of Michael Jerman from the Board and his role as Chair of the Audit Committee, effective November 18, 2024. The company simultaneously appointed Matthew Pratt Whalen, a CPA with extensive CFO experience, to the Board and as the new Audit Committee Chair.
๐ฉ Red Flags
- Sudden departure of the Audit Committee Chair.
๐ Key Facts
- Michael Jerman resigned from the Board and the Audit Committee on November 18, 2024.
- The resignation was stated to be for 'other activities' and not due to any disagreement with the Company.
- Matthew Pratt Whalen appointed as a Director and Chairman of the Audit Committee effective November 18, 2024.
- Whalen is a CPA with over 20 years of experience, currently CFO of Power Digital Marketing Inc. and director at Telmoir Pharmaceuticals (NASDAQ: TELO).
MIRA Pharmaceuticals announced the selection of The Centre for Human Drug Research (CHDR) in the Netherlands as the clinical trial site for its Ketamir-2 Phase I/IIa study. The company plans to begin recruitment in Q1 2025, utilizing proprietary PainCartยฎ technology to assess efficacy and safety.
๐ Key Facts
- Selected The Centre for Human Drug Research (CHDR) in Leiden, Netherlands as the trial site for Ketamir-2.
- Ketamir-2 is a novel oral ketamine analog targeting pain management.
- Recruitment for Phase I study in healthy subjects is scheduled to begin in Q1 2025.
- Initial safety and efficacy results from Phase I are expected in H2 2025.
- Phase IIa study focusing on diabetic neuropathy patients is planned for Q4 2025, with results anticipated in H1 2026.
- The trial will utilize CHDR's proprietary PainCartยฎ technology to measure pain response.
Mira Pharmaceuticals reported positive preclinical results for its novel ketamine analog, Ketamir-2, demonstrating 60% greater efficacy than gabapentin in a model of chemotherapy-induced neuropathic pain. The company is looking to expand studies into diabetic neuropathy and PTSD while seeking government funding.
๐ Key Facts
- Ketamir-2 demonstrated 60% greater efficacy than FDA-approved gabapentin in preclinical models for chemotherapy-induced neuropathic pain.
- The drug is a novel oral ketamine analog.
- Company plans to advance development into diabetic neuropathy and PTSD.
- Management is exploring government funding opportunities to support the program.
MIRA Pharmaceuticals reported positive preclinical results for its oral ketamine analog, Ketamir-2, showing superior efficacy against Gabapentin and Pregabalin in neuropathic pain models. The company is targeting an IND application by year-end 2024 with Phase I trials expected in Q1 2025.
๐ฉ Red Flags
- High reliance on preclinical data which does not guarantee clinical success.
- Significant timeline risk: Clinical trial phases are highly speculative and subject to regulatory delays.
๐ Key Facts
- Ketamir-2 demonstrated significantly greater efficacy than FDA-approved Gabapentin (Neurontin) and Pregabalin (Lyrica) in preclinical models of neuropathic pain.
- Company is conducting additional studies for chemotherapy-induced and diabetic neuropathy.
- Plans to initiate PTSD trials; exploring government funding opportunities for the PTSD program.
- Targeting IND application submission by end of 2024.
- Phase I clinical trials projected to begin in Q1 2025.
- Phase II clinical trials projected to start by late 2025.
MIRA Pharmaceuticals, Inc. held its 2024 Annual Meeting of Stockholders on September 12, 2024. The meeting resulted in the election of five directors and the ratification of the company's independent auditor.
๐ Key Facts
- Annual Meeting held on September 12, 2024; quorum was established with 9,418,088 shares voted (63.72% of outstanding).
- Five directors were elected: Erez Aminov, Michael Jerman, Matthew Del Giudice, M.D., Denil Nanji Shekhat, M.D., and Edward MacPherson.
- Cherry Bekaert LLP was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2024.
- Stockholders approved amendments to the 2022 Omnibus Incentive Plan to increase available shares.
- Proposal 4 regarding an adjournment of the meeting was withdrawn as proposals were successfully passed.
Mira Pharmaceuticals has selected neuropathic pain as the primary indication for its oral ketamine analog, Ketamir-2. The company has submitted a pre-IND meeting request to the FDA and expects the meeting to take place in October 2024.
๐ Key Facts
- Selected neuropathic pain as the primary indication for Ketamir-2 (oral ketamine analog).
- Submitted a pre-Investigational New Drug (pre-IND) meeting request to the FDA.
- FDA meeting anticipated in October 2024.
- Plans to begin human trials in Q1 2025.
Mira Pharmaceuticals announced positive preclinical results for its oral ketamine analog, Ketamir-2, demonstrating significant pain reversal in a rat model of neuropathic pain. The study suggests superior efficacy compared to oral ketamine at high doses.
๐ฉ Red Flags
- Results are preclinical (animal model) and do not guarantee success in human clinical trials.
๐ Key Facts
- Preclinical study conducted on a rat model of nerve-ligation induced neuropathic pain.
- Low oral doses of Ketamir-2 led to significant reversal of mechanical allodynia for 14 and 22 days post-operation.
- Highest dose achieved 100% normalization of the pain threshold (complete reversal of pain signal).
- Ketamir-2 outperformed oral ketamine, which failed to provide significant relief under the same conditions.
Mira Pharmaceuticals announced positive preclinical data for its drug candidate Ketamir-2 and its metabolite Nor-Ketamir, noting improved bioavailability in a new salt formulation. The company plans to submit an IND application by the end of 2024.
๐ Key Facts
- Preclinical data shows Nor-Ketamir selectively interacts with the NMDA PCP site while avoiding glutamate NMDA site activity.
- Development of Ketamir-2 Pamoate salt formulation achieved nearly 100% oral bioavailability and improved brain penetration.
- Company is currently progressing with IND-enabling regulatory work and GMP drug scale-up.
- Targeting IND application submission by the end of 2024 to initiate clinical trials.
Mira Pharmaceuticals, Inc. has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2). The company is now in good standing regarding this specific listing standard.
๐ฉ Red Flags
- Previous non-compliance with minimum bid price requirements indicates past volatility or low share price issues.
๐ Key Facts
- Notification received from Nasdaq on August 7, 2024.
- Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) (minimum bid price requirement).
- The company is currently in good standing with all applicable Nasdaq listing requirements.
Mira Pharmaceuticals, Inc. disclosed positive preclinical data for its novel oral ketamine analog, Ketamir-2, highlighting a selective NMDA receptor binding mechanism. The company aims to submit an Investigational New Drug (IND) application to the FDA later this year.
๐ Key Facts
- Ketamir-2 shows 30-50-fold lower affinity to the PCP site compared with ketamine, potentially reducing side effects like dissociation and hallucinations.
- Preclinical studies in rats and dogs showed no toxicity at very high doses.
- The compound exhibits antidepressant and anxiolytic activities at oral doses 5-10x lower than toxicology test levels.
- Company plans to submit an Investigational New Drug (IND) application to the FDA later in 2024.
Mira Pharmaceuticals announced positive preclinical data for its novel oral ketamine analog, Ketamir-2. The company intends to use this data to support an upcoming Investigational New Drug (IND) application to the FDA by year-end 2024.
๐ฉ Red Flags
- No immediate red flags detected; filing is a standard promotional update regarding preclinical progress.
๐ Key Facts
- Preclinical testing of Ketamir-2 shows it is not a substrate for P-glycoprotein (P-gp), potentially allowing for better blood-brain barrier penetration than traditional ketamine.
- Predicted oral bioavailability for Ketamir-2 is approximately 80%, compared to <30% for traditional ketamine.
- Preclinical models suggest reduced risk of hyper-locomotor activity and no interaction with mu-opioid receptors, potentially lowering dependency risks.
- The company plans to submit an IND application to the FDA by the end of 2024.
- Ongoing studies are exploring efficacy for chemotherapy-induced depression and cancer-related neuropathic pain.
MIRA Pharmaceuticals received a notice from Nasdaq stating it is non-compliant with the minimum $1.00 bid price requirement after trading below that level for 30 consecutive business days (May 22, 2024 โ July 5, 2024). The company has a 180-day compliance period ending January 6, 2025, to regain compliance.
๐ฉ Red Flags
- Delisting notice from Nasdaq (Minimum Bid Requirement violation).
- Potential for delisting if compliance is not met by January 6, 2025.
- Significant stock price depression (trading below $1.00).
๐ Key Facts
- Received Nasdaq notice on July 8, 2024, regarding violation of Rule 5550(a)(2).
- Closing bid price fell below $1.00 for 30 consecutive business days between May 22 and July 5, 2024.
- Compliance period expires on January 6, 2025; must maintain $1.00+ for 10 consecutive business days to cure.
- Company plans to submit an IND for Ketamir-2 by the end of 2024 and initiate human trials in Q1 2025.
- Reported positive preclinical results for MIRA-55, showing enhanced efficacy over THC in anxiety models.
MIRA Pharmaceuticals, Inc. announced an amended employment agreement for CFO Michelle Yanez, which includes a significant reduction in base salary and permission for her to serve as CFO of another entity controlled by Bay Shore Trust.
๐ฉ Red Flags
- Significant reduction in executive compensation (approx. 39% decrease) often signals liquidity constraints or cost-cutting measures.
- Potential conflict of interest/split focus: The CFO is simultaneously serving as CFO for another entity (Telomir Pharmaceuticals, Inc.) controlled by a related party (Bay Shore Trust).
- Reduced commitment level: The requirement to work only 30 hours per week suggests the CFO's attention is being divided.
๐ Key Facts
- CFO Michelle Yanez's annual base salary reduced from $225,000 to $137,500 effective June 26, 2024.
- The amended agreement requires a minimum of 30 hours per week dedicated to MIRA Pharmaceuticals.
- Ms. Yanez is permitted to provide services to other companies owned/controlled by Bay Shore Trust, specifically Telomir Pharmaceuticals, Inc., where she was appointed CFO on June 18, 2024.
- The company's first Annual Meeting of Shareholders is scheduled for September 12, 2024.
Mira Pharmaceuticals, Inc. announced a Second Amendment to the employment agreement of CEO Erez Aminov, effective May 28, 2024. The amendment includes a salary increase and updated severance/acceleration terms in the event of termination or change of control.
๐ฉ Red Flags
- Increased executive compensation/severance obligations in an emerging growth company context.
๐ Key Facts
- CEO Erez Aminov's annual base salary increased to $300,000 effective June 1, 2024.
- Severance package includes a lump sum payment (75% of base salary) plus 6 months of salary continuation in the event of termination without cause or good reason resignation.
- Includes 12 months of accelerated vesting for outstanding unvested stock options upon termination without cause/good reason.
- Enhanced severance terms if terminated within 18 months following a Change of Control, including 1.5x (Base Salary + Target Bonus) as a lump sum and 12 months of accelerated option vesting.
Mira Pharmaceuticals underwent a significant restructuring of its Board and executive leadership, including the resignation of the Executive Chairman/CEO (Dr. Chris Chapman) and the President/Chief Scientific Officer (Adam Kaplin). The company is replacing these roles with new board members and an external consultant to bolster scientific expertise for upcoming IND filings.
๐ฉ Red Flags
- Mass resignation of multiple board members and key executives within a single week.
- Departure of the Executive Chairman/CEO to focus on another company (Telomir Pharmaceuticals).
- Loss of the President and Chief Scientific Officer, which is critical for a biotech company aiming for IND filings.
๐ Key Facts
- On March 9, 2024, three board members (Talhia Tuck, Brad Kroenig, Hugh McColl) voluntarily resigned.
- Dr. Chris Chapman resigned as Executive Chairman and employee effective March 9, 2024, to focus on Telomir Pharmaceuticals.
- Adam Kaplin, M.D., Ph.D., resigned as President and Chief Scientific Officer effective March 7, 2024.
- Erez Aminov (CEO) appointed as Chairman of the Board on March 13, 2024.
- Three new board members were appointed: Dr. Matthew P. Del Giudice, Dr. Denil N. Shekhat, and Mr. Ned MacPherson.
- The company entered into an Amended and Restated Consulting Agreement with Angel Pharmaceutical Consulting & Technologies Ltd (APCT).
- Dr. Itzchak Angel will serve as the Companyโs Chief Scientific Advisor.
Mira Pharmaceuticals reports that its previously disclosed positive pre-clinical study results for 'MIRA1a' were actually based on a different, unintended molecule discovered during manufacturing, now named 'MIRA-55'. While the company claims MIRA-55 may be more potent, all prior clinical data reported in SEC filings is technically attributable to this new substance rather than the patented MIRA1a.
๐ฉ Red Flags
- Material discrepancy: Previous clinical data reported in SEC filings (S-1 Registration Statements) does not apply to the intended molecule (MIRA1a).
- Manufacturing/Quality Control failure: The unintended synthesis occurred during the manufacturing and scale-up process by third-party manufacturers.
- Intellectual Property risk: While a provisional patent for MIRA-55 was filed, the company's core asset value is now tied to a molecule that was not the original subject of its primary patent/research strategy.
๐ Key Facts
- The company's intended drug candidate, MIRA1a, was inadvertently synthesized as a different molecule, 'MIRA-55', during manufacturing and scale-up processes.
- All previously disclosed positive pre-clinical testing results in Registration Statements (effective Aug 2023 and Dec 2023) were actually based on the MIRA-55 compound.
- The company filed a provisional patent application for MIRA-55 in early March 2024 to seek global protection.
- MIRA-55 is being advanced as the new lead compound, while the company retains rights to the original MIRA1a patent.
Mira Pharmaceuticals, Inc. announced the resignation of Christos Nicholoudis from the Board of Directors and his role as part-time General Counsel effective January 15, 2024.
๐ Key Facts
- Christos Nicholoudis resigned from the Board of Directors on January 15, 2024.
- Mr. Nicholoudis also stepped down from his role as part-time General Counsel.
- The resignation was not due to any disagreements with the Company, management, or the Board regarding operations, policies, or practices.